background
rhinovirusinduc
acut
asthma
frequent
trigger
asthma
exacerb
object
assess
inflammatori
mediat
releas
bronchial
epitheli
cell
bec
infect
rhinoviru
determin
whether
also
present
subject
acut
virusinduc
asthma
aim
identifi
biomark
biomark
acut
virusinduc
asthma
method
bec
obtain
bronchial
brush
steroidna
asthmat
subject
healthi
nonatop
control
subject
cell
infect
rhinoviru
inflammatori
mediat
measur
mean
flow
cytometri
cytometr
bead
array
subject
acut
asthma
viru
infect
recruit
character
clinic
use
lung
function
test
blood
taken
measur
inflammatori
mediat
identifi
import
bec
experi
result
ifnginduc
protein
rant
releas
greatest
quantiti
follow
tnfa
dexamethason
treatment
bec
partial
suppress
tnfa
effect
suppress
rant
acut
clinic
asthma
serum
level
increas
greater
extent
acut
virusinduc
asthma
median
pgml
compar
pgml
nonvirusinduc
acut
asthma
p
increas
serum
level
predict
virusinduc
asthma
odd
ratio
ci
increas
serum
level
strongli
associ
sever
airflow
obstruct
r
p
conclus
releas
specif
acut
virusinduc
asthma
clinic
implic
measur
serum
could
use
predict
viral
trigger
acut
asthma
j
allergi
clin
immunol
viral
respiratori
tract
infect
common
trigger
asthma
exacerb
includ
sever
requir
hospit
human
rhinovirus
frequent
isol
pathogen
cohort
children
high
risk
asthma
rhinovirusinduc
lower
respiratori
tract
symptom
strongest
predictor
recurr
wheez
although
treatment
corticosteroid
clearli
improv
longterm
asthma
control
appear
significantli
less
effect
prevent
virusassoci
acut
exacerb
diseas
children
adult
virusinduc
acut
asthma
associ
specif
inflammatori
phenotyp
character
neutrophil
inflamm
directli
relat
clinic
sever
also
appear
respond
less
well
treatment
corticosteroid
observ
support
find
moder
dose
inhal
steroid
partial
affect
airway
inflamm
experiment
rhinovirusinduc
asthma
clinic
observ
suggest
rhinoviru
infect
abil
induc
specif
inflammatori
respons
predispos
individu
result
worsen
asthmat
symptom
increas
airway
inflamm
poorli
control
current
treatment
corticosteroid
therefor
abil
clearli
identifi
group
clinic
import
new
treatment
target
develop
virusinduc
acut
asthma
bec
bronchial
epitheli
cell
ifnginduc
protein
lr
likelihood
ratio
nfkb
nuclear
factor
kb
rhinoviru
tcid
tissu
cultur
infecti
dose
bronchial
epithelium
activ
particip
inflammatori
process
asthma
import
sourc
autacoid
mediat
chemokin
growth
factor
also
epithelium
target
rhinoviru
infect
result
releas
numer
proinflammatori
factor
reason
propos
rhinoviru
infect
epithelium
would
induc
specif
inflammatori
chemokin
cytokin
would
act
signatur
acut
virusinduc
asthma
use
primari
bronchial
epitheli
cell
bec
model
rhinoviru
infect
determin
whether
specif
mediat
releas
rhinoviru
infect
whether
differ
quantit
qualit
bec
deriv
asthmat
subject
recruit
subject
acut
asthma
determin
acut
rhinovirusinduc
viral
induc
asthma
sought
whether
similar
specif
respons
could
seen
serum
inflammatori
mediat
relat
clinic
sever
design
studi
necessit
recruit
separ
group
subject
asthma
group
howev
asthma
diagnos
atop
individu
consist
histori
asthma
evid
bronchial
hyperrespons
defin
pc
histamin
valu
mgml
categor
accord
global
initi
asthma
guidelin
addit
subject
nonsmok
use
bec
model
mimic
acut
natur
infect
essenti
subject
stabl
asthma
respiratori
tract
infect
preced
week
demonstr
vivo
effect
rhinoviru
infect
recruit
subject
acut
asthma
age
year
within
hour
present
emerg
depart
previou
diagnosi
asthma
abl
perform
spirometri
nonsmok
asthma
confirm
week
later
mean
bronchial
provoc
test
atopi
confirm
mean
allergi
skin
prick
test
emerg
depart
subject
underw
spirometri
administr
bronchodil
subject
given
mg
salbutamol
administ
metereddos
inhal
spacer
respons
bronchodil
measur
minut
subject
studi
week
exacerb
procedur
repeat
subject
provid
written
inform
consent
protocol
approv
relev
local
ethic
committe
volunt
vitro
cultur
phase
studi
primari
bec
obtain
mean
fiberopt
bronchoscopi
accord
standard
guidelin
cell
cultur
perform
previous
describ
primari
cultur
establish
seed
freshli
brush
bec
hormon
supplement
bronchial
epitheli
growth
medium
clonet
san
diego
calif
contain
uml
penicillin
mgml
streptomycin
passag
cell
seed
onto
tray
cultur
confluent
exposur
rhinoviru
neg
control
cell
treat
medium
alon
uvinactiv
pretreat
hour
dexamethason
nmoll
supernat
bec
remov
measur
rant
ifnginduc
protein
tnfa
carri
use
multiplex
cytokin
analysi
carri
facscan
bectondickinson
franklin
lake
nj
cytometr
bead
array
system
bectondickinson
confirm
mean
elisa
blood
collect
present
week
later
serum
assay
rant
use
elisa
biosourc
intern
camarillo
calif
see
method
section
articl
onlin
repositori
wwwjacionlineorg
stock
gener
titrat
cultur
ohio
hela
cell
describ
previous
primari
bec
cultur
infect
multipl
infect
confirm
infect
quantif
viral
product
assess
use
hela
titrat
assay
subject
acut
asthma
throat
swab
immers
rlt
buffer
extract
purif
rna
perform
rtpcr
perform
detect
common
respiratori
virus
influenza
b
rv
coronaviru
parainfluenza
respiratori
syncyti
viru
human
metapneumoviru
adenoviru
throat
swab
demonstr
similar
sensit
viru
detect
previous
describ
induc
sputum
statist
analysi
data
describ
mean
sd
frequenc
percentag
continu
categor
variabl
median
interquartil
rang
use
instead
mean
sd
data
nonnorm
distribut
student
test
mannwhitney
test
appropri
use
determin
differ
inflammatori
biomark
group
univari
correl
analyz
use
spearman
rank
test
receiv
oper
curv
analysi
appli
assess
optim
cutoff
inflammatori
biomark
detect
viru
infect
odd
ratio
posit
likelihood
ratio
along
confid
interv
estim
primari
bec
healthi
control
subject
inhal
corticosteroidna
asthmat
subject
use
experi
subject
characterist
shown
tabl
articl
onlin
repositori
www
jacionlineorg
supernat
remov
hour
infect
signific
increas
rant
tnfa
level
seen
baselin
valu
evid
hour
peak
hour
infect
see
fig
articl
onlin
repositori
wwwjacionlineorg
experi
includ
neg
control
uvinactiv
signific
induct
seen
condit
see
fig
articl
onlin
repositori
wwwjacionlineorg
induct
across
time
point
thymu
activationregul
chemokin
eotaxin
ifng
releas
inflammatori
mediat
primari
bec
compar
subject
asthma
healthi
control
subject
hour
infect
signific
differ
found
group
induct
mediat
compar
greatest
induct
seen
level
asthmat
bec
releas
median
pgml
compar
pgml
seen
healthi
control
cell
p
see
fig
b
articl
onlin
repositori
wwwjacionlineorg
rant
induc
bec
asthmat
subject
pgml
healthi
control
subject
pgml
p
see
fig
corticosteroid
primari
agent
use
suppress
airway
inflamm
asthma
examin
effect
pretreat
bec
infect
rhinoviru
use
dexamethason
concentr
nmoll
effect
dexamethason
inflammatori
respons
rhinoviru
vari
differ
mediat
see
tabl
also
fig
articl
onlin
repositori
wwwjacionlineorg
case
rant
treatment
nm
dexamethason
led
median
reduct
case
led
median
reduct
howev
case
nmoll
dexamethason
significantli
reduc
releas
compar
rhinoviru
infect
alon
cell
treat
nmoll
effect
median
reduct
tnfa
requir
treatment
nmoll
suppress
releas
compar
rhinoviru
infect
alon
infect
primari
bec
confirm
remov
supernat
time
point
estim
tissu
cultur
infecti
dose
tcid
hela
titrat
assay
rhinoviru
replic
hour
infect
significantli
greater
bec
asthmat
subject
median
tcid
ml
compar
healthi
control
subject
tcid
ml
p
examin
whether
relationship
level
rant
releas
rhinoviru
replic
mean
univari
analysi
posit
correl
releas
tcid
ml
valu
r
p
rant
r
p
signific
correl
rhinoviru
replic
tnfa
level
sought
determin
pattern
inflammatori
mediat
releas
sera
subject
acut
asthma
determin
whether
acut
virusinduc
asthma
could
differenti
noninfect
acut
asthma
recruit
subject
present
emerg
depart
diagnosi
acut
asthma
period
potenti
subject
smoker
exclud
nonatop
evid
bronchial
respons
fail
attend
followup
visit
exclud
final
analysi
left
subject
acut
asthma
exacerb
subject
found
viral
respiratori
tract
infect
trigger
acut
asthma
major
subject
acut
virusinduc
asthma
rhinoviru
isol
n
subject
present
coronaviru
present
influenza
present
rhinoviru
influenza
see
tabl
articl
onlin
repositori
www
jacionlineorg
compar
subject
present
acut
asthma
histori
viral
upper
respiratori
tract
infect
neg
pcr
result
respiratori
virus
subject
acut
virusinduc
asthma
lower
median
fev
predict
valu
bronchodil
compar
nonvirusinduc
acut
asthma
p
see
tabl
articl
onlin
repositori
wwwjacionlineorg
addit
group
compar
term
chang
fev
minut
administr
bronchodil
acut
virusinduc
asthma
less
respons
bronchodil
median
chang
significantli
less
nonvirusinduc
acut
asthma
p
see
tabl
articl
onlin
repositori
www
jacionlineorg
acut
virusinduc
asthma
significantli
increas
median
serum
level
pgml
interquartil
rang
compar
nonvirusinduc
acut
asthma
pgml
interquartil
rang
p
fig
tabl
ii
serum
level
significantli
differ
acut
virusinduc
asthma
nonvirusinduc
acut
asthma
tabl
ii
serum
rant
level
less
limit
detect
subject
serum
tnfa
level
demonstr
trend
toward
higher
valu
subject
nonvirusinduc
acut
asthma
pgml
interquartil
rang
compar
patient
virusinduc
acut
asthma
pgml
interquartil
rang
wide
variat
signific
p
level
serum
mediat
increas
acut
asthma
compar
stabl
diseas
measur
week
recoveri
acut
event
tabl
ii
examin
separ
acut
rhinovirusinduc
asthma
still
significantli
increas
serum
level
pgml
interquartil
rang
compar
nonvirusinduc
acut
asthma
p
addit
signific
induct
pgml
interquartil
rang
given
serum
tnfa
level
clearli
differ
subject
acut
virusinduc
asthma
compar
nonvirusinduc
asthma
investig
whether
could
use
diagnos
acut
virusinduc
asthma
receiv
oper
characterist
analysi
use
determin
optim
cutoff
inflammatori
marker
differenti
virusinduc
nonviru
induc
asthma
optim
cutoff
pgml
area
curv
ci
valu
greater
threshold
indic
viral
trigger
sensit
specif
posit
likelihood
ratio
lr
neg
lr
optim
cutoff
tnfa
pgml
area
curv
ci
valu
less
level
indic
viral
trigger
sensit
specif
posit
lr
neg
lr
combin
marker
yield
even
power
test
thu
serum
level
greater
serum
level
strongli
associ
acut
virusinduc
asthma
assess
relationship
airflow
obstruct
strong
neg
correl
serum
level
lower
initi
fev
r
p
see
fig
articl
onlin
repositori
wwwjacionlineorg
addit
strong
neg
correl
serum
level
percentag
chang
fev
minut
bronchodil
administr
r
p
suggest
higher
serum
level
associ
reduc
respons
shortact
bronchodil
also
signific
although
weaker
correl
acut
fev
r
p
r
p
level
signific
correl
tnfa
level
confirm
infect
bec
taken
subject
allerg
asthma
nonatop
healthi
control
subject
respond
infect
releas
larg
quantiti
rant
smaller
amount
tnfa
releas
rant
associ
vitro
rhinoviru
replic
differ
seen
subject
asthma
healthi
control
subject
although
substanti
withingroup
variat
context
sever
acut
asthma
subject
present
emerg
depart
serum
level
acut
increas
sera
acut
virusinduc
asthma
increas
serum
level
combin
low
tnfa
level
predict
virusinduc
caus
trigger
acut
asthma
final
level
serum
present
subject
acut
asthma
strongli
associ
sever
airflow
obstruct
reduc
b
agonist
bronchodil
respons
initi
emerg
depart
present
although
rhinoviru
infect
epithelium
lead
widespread
epitheli
desquam
propos
cold
symptom
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
trigger
virusinduc
releas
proinflammatori
mediat
previou
vitro
studi
rhinoviru
infect
human
cultur
airway
epithelium
shown
virusspecif
induct
releas
rant
gmcsf
tnfa
find
support
increas
mediat
found
natur
rhinoviru
infect
experiment
rhinoviru
infect
asthma
work
confirm
find
knowledg
first
extend
examin
respons
primari
bec
deriv
subject
asthma
nonatop
control
subject
unabl
detect
differ
group
although
observ
substanti
withingroup
variat
mediat
respons
inher
variat
seen
within
group
due
test
inaccuraci
excel
agreement
separ
mediat
detect
method
elisa
flow
cytometri
experi
perform
duplic
mediat
show
greatest
magnitud
respons
rant
rant
import
chemoattract
eosinophil
lymphocyt
overexpress
allerg
airway
inflamm
vitro
induct
rant
rhinoviru
infect
bec
shown
specif
replic
viru
trigger
rhinoviru
rna
close
relat
level
viral
replic
bec
howev
rant
product
bec
also
occur
consequ
exposur
hous
dust
mite
allergen
der
p
therefor
specif
viru
infect
chemokin
ligand
shown
induc
bec
infect
close
link
rhinoviru
replic
mechan
depend
prior
induct
either
ifng
type
ifn
ifna
ifnb
suggest
releas
might
trigger
doublestrand
viral
rna
react
tolllik
receptor
lead
transloc
nuclear
factor
kb
nucleu
activ
tolllik
receptor
shown
lead
transloc
ifn
respons
factor
induc
product
valu
express
median
interquartil
rang
significantli
differ
nonvirusinduc
acut
asthma
present
p
mannwhitney
u
test
significantli
differ
result
obtain
acut
visit
p
wilcoxon
signedrank
test
ifnb
support
found
correl
level
rant
releas
along
rhinoviru
replic
bec
howev
rhinoviru
replic
much
greater
bec
asthmat
subject
independ
inflammatori
respons
also
seen
previous
demonstr
bec
asthmat
subject
suscept
infect
rhinoviru
respond
infect
defici
type
ifn
respons
associ
increas
cytolysi
directli
relat
enhanc
rhinoviru
replic
result
therefor
support
concept
bec
asthmat
subject
defici
innat
immun
respons
adequ
react
level
rhinoviru
replic
although
still
capabl
releas
suffici
inflammatori
mediat
recruit
activ
inflammatori
cell
airway
worsen
tissu
injuri
interact
receptor
highli
express
activ
natur
killer
cell
stimul
direct
migrat
cell
cell
express
usual
associ
site
h
inflamm
even
report
antagonist
h
cell
ovasensit
mous
model
overexpress
decreas
releas
eosinophil
recruit
airway
howev
administ
exogen
lung
mice
alreadi
establish
allerg
inflamm
increas
eosinophil
accumul
lung
increas
level
although
airway
respons
initi
dampen
rebound
hour
howev
exclus
h
cell
low
level
express
h
cell
h
cell
activ
appear
select
recruit
airway
event
clearli
indic
individu
establish
allerg
inflamm
capabl
worsen
preexist
asthmat
airway
inflamm
associ
tnfa
might
lead
mark
worsen
airway
inflamm
epitheli
permeabl
particular
note
tnfa
sensit
suppress
dexamethason
although
rant
product
keep
experiment
find
moder
dose
inhal
corticosteroid
effect
reduc
bronchial
hyperrespons
infiltr
eosinophil
prevent
accumul
cytotox
cell
within
airway
experiment
infect
involv
acut
virusinduc
asthma
might
identifi
signal
pathway
respons
treatment
corticosteroid
help
explain
lack
efficaci
caus
acut
asthma
sought
determin
whether
earli
event
result
bec
infect
also
led
similar
pattern
mediat
releas
sera
subject
present
acut
asthma
use
cohort
present
emerg
depart
acut
asthma
increas
level
highli
specif
acut
asthma
evid
viru
infect
level
serum
rant
detect
might
part
explain
vitro
observ
product
cytokin
effect
suppress
corticosteroid
nearli
subject
acut
asthma
regularli
use
inhal
corticosteroid
might
suffici
reduc
rant
releas
suffici
reduc
releas
keep
bec
model
saw
suppress
higher
dose
dexamethason
presenc
increas
serum
level
highli
specif
acut
virusinduc
asthma
exacerb
although
rhinoviru
seem
induc
smaller
increas
level
virus
increas
level
pgml
higher
power
predict
virustrigg
asthma
exacerb
suggest
serum
level
use
differenti
acut
virusinduc
asthma
nonvirusinduc
acut
asthma
although
moment
specif
antivir
therapi
undergon
trial
acut
virusinduc
asthma
effect
antirhinoviru
agent
exist
simpl
blood
test
identifi
might
benefit
would
instrument
allow
trial
go
forward
control
group
without
asthma
upper
respiratori
tract
infect
unabl
determin
whether
magnitud
increas
level
greater
asthmat
nonasthmat
subject
viral
infect
elsewher
bodi
might
also
induc
releas
induct
well
character
chronic
hepat
c
infect
even
use
predict
respons
treatment
ifn
ribavarin
therefor
viral
infect
would
like
also
induc
increas
serum
level
reduc
specif
predict
acut
virusinduc
asthma
howev
unlik
clinic
subject
viral
infect
recruit
adult
report
symptom
recent
upper
respiratori
tract
infect
none
subject
anoth
acut
ill
present
enquir
possibl
chronic
viral
infect
hepat
b
c
believ
unlik
presenc
would
confound
result
circumst
fact
level
decreas
dramat
followup
highli
suggest
directli
relat
acut
trigger
chronic
infect
preval
sampl
children
age
year
hospit
wheez
ill
associ
rhinoviru
tend
like
atop
subject
higher
level
serum
ige
would
interest
address
futur
studi
whether
relationship
intens
inflammatori
respons
acut
virusinduc
asthma
preexist
level
allerg
sensitis
level
ige
result
also
shed
import
light
pathogenesi
acut
rhinovirusinduc
asthma
magnitud
releas
close
relat
sever
acut
airflow
obstruct
known
airflow
obstruct
occur
asthma
time
exacerb
character
lower
lung
function
less
variabl
histori
viral
infect
associ
gradual
worsen
asthma
appear
less
respons
acut
bronchodil
presenc
mast
cell
within
airway
specif
within
airway
smooth
muscl
layer
pathognomon
featur
asthma
cell
express
receptor
known
ligand
moreov
stimul
asthmat
smooth
muscl
cell
produc
control
cell
exposur
human
mast
cell
cell
enhanc
vitro
migrat
process
neutral
block
therefor
viral
infect
bronchial
epithelium
might
lead
earli
releas
set
chain
event
enhanc
preexist
asthmat
airway
inflamm
encourag
migrat
activ
mast
cell
airway
smooth
muscl
layer
therebi
worsen
bronchoconstrict
reduc
respons
bronchodil
unclear
howev
serum
tnfa
level
higher
nonvirusinduc
acut
asthma
subject
sever
asthma
known
higher
level
tnfa
subject
milder
asthma
might
nonvirusinduc
asthma
inher
unstabl
chronic
asthma
predispos
exacerb
although
lower
lung
function
use
higher
dose
inhal
corticosteroid
might
also
simpli
nonvirusinduc
acut
trigger
led
greater
induct
tnfa
virusinduc
acut
asthma
conclus
result
shown
use
vitro
model
primari
bec
rhinoviru
capabl
initi
intens
inflammatori
respons
bec
mark
releas
rant
correl
vitro
rhinoviru
replic
confirm
use
cohort
acut
asthmat
subject
increas
serum
releas
appear
highli
specif
virusinduc
acut
asthma
also
associ
sever
airflow
obstruct
reduc
bronchodil
respons
result
demonstr
perhap
combin
tnfa
might
use
clinic
maker
identifi
rhinovirusand
virusinduc
induc
acut
asthma
suggest
either
promin
role
worsen
airflow
obstruct
airway
inflamm
acut
rhinovirusinduc
asthma
highlight
potenti
therapeut
target
